Antibodies News and Research

RSS

Complex SARS-CoV-2 serology means universal immunological assay is not feasible

As we improve our understanding of immune responses and correlates of protection against the severe acute respiratory syndrome coronavirus (SARS-CoV-2), two UK researchers emphasize that we will probably utilize different assays to tackle specific questions. Their commentary is published in the prestigious journal Lancet Infectious Diseases.

27 Sep 2020

New trial tests combination antibody treatment for preventing COVID-19 illness

A combination antibody treatment for preventing COVID-19 illness in individuals who have had sustained exposure to someone with the virus is being studied by researchers at The University of Texas Health Science Center at Houston.

25 Sep 2020

Ultrapotent antibody mix locks infection machinery, inhibits SARS-CoV-2 attachment to cells

A mix of ultrapotent antibodies from recovered COVID-19 patients has been shown to recognize and lock down the infection machinery of the pandemic coronavirus and keep it from entering cells. Each of the antibody types performs these overlapping tasks slightly differently.

25 Sep 2020

New diagnostic tool may allow on-the-spot detection of coronavirus infection

Scientists at the University of Warwick have demonstrated that a potential diagnostic tool for detecting Covid-19 using sugars will work with a virus rather than just its proteins, a significant step in making it a viable test in future.

25 Sep 2020

Patients with severe COVID-19 have antibodies blocking body's important defense mechanisms

Persons with critical corona-disease may have antibodies blocking the body´s most important defence mechanisms.

25 Sep 2020

About 10% patients with severe disease create auto-antibodies that attack the immune system

People infected by the novel coronavirus can have symptoms that range from mild to deadly. Now, two new analyses suggest that some life-threatening cases can be traced to weak spots in patients' immune systems.

25 Sep 2020

BIOCAD to produce liquid vaccine for COVID-19 treatment

Clinical trials of the vaccine are currently underway. The &laquoSputnik V» is the two-component vaccine. Revaccination is carried out at intervals of 3-4 weeks. Moreover, with the repeated introduction of a particle of coronavirus RNA, it is covered with a new adenovirus.

25 Sep 2020

Faulty genes and an autoimmune condition linked to severe COVID-19 in young, healthy people

More than 10 percent of young and healthy people who develop severe COVID-19 have misguided antibodies that attack not the virus, but the immune system itself, new research shows. Another 3.5 percent, at least, carry a specific kind of genetic mutation.

25 Sep 2020

Individuals with severe forms of COVID-19 disease can have compromised type I interferon responses

Individuals with severe forms of COVID-19 disease can present with compromised type I interferon (IFN) responses based on their genetics, according to results published in two papers today in the journal Science.

25 Sep 2020

New study may explain why more men than women die from COVID-19

New findings by scientists at the National Institutes of Health and their collaborators help explain why some people with COVID-19 develop severe disease.

25 Sep 2020

Berlin researchers are pursuing the development of passive vaccination

Researchers at the German Center for Neurodegenerative Diseases (DZNE) and Charité - Universitätsmedizin Berlin have identified highly effective antibodies against the coronavirus SARS-CoV-2 and are now pursuing the development of a passive vaccination.

25 Sep 2020

New antibodies protect mice against lethal infections of influenza B virus

Researchers have identified two antibodies that protect mice against lethal infections of influenza B virus, report scientists at Washington University School of Medicine in St. Louis and Icahn School of Medicine at Mount Sinai.

24 Sep 2020

A possible inverse relationship between Dengue and COVID-19 in Brazil

Their study titled, “How super-spreader cities, highways, hospital bed availability, and dengue fever influenced the COVID-19 epidemic in Brazil,” was released pre-peer review on the preprint medRxiv* early this week.

24 Sep 2020

Tokyo citizens may have developed COVID-19 herd immunity, say researchers

Researchers in Japan and the United States have conducted a study showing that herd immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have developed among the citizens of Tokyo during the summer.

24 Sep 2020

Challenges in High Complexity Flow Cytometry

In this interview, Dra. Mª José Marco from the Department of Hematology at Hopsital Dr. Peset talks to News-Medical Life Sciences about high complexity flow cytometry and the challenges they often face.

From Beckman Coulter Life Sciences - Flow Cytometry 24 Sep 2020

Research says in SARS-CoV-2 canine infection, transmission unlikely

A new study published on the preprint server bioRxiv* in September 2020 shows that pet dogs have been falling sick and dying of a mysterious respiratory infection, often showing the presence of anti- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, even though in many cases they do not test positive for COVID-19.

24 Sep 2020

Brazil becomes global hotspot for COVID-19 pandemic

Two nationwide COVID-19 antibody seroprevalence studies from Brazil show that many cities along the Amazon were hit hardest at the beginning of the epidemic in May and June, along with poorer and Indigenous communities.

24 Sep 2020

FDA issues emergency use authorization for first serology point-of-care test for COVID-19

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the first serology (antibody) point-of-care (POC) test for COVID-19.

24 Sep 2020

Siemens’ SARS-CoV-2 antibody immunoassays meet regulatory targets

New research being presented at the ESCMID Conference on Coronavirus Disease (ECCVID, online 23-25 September) shows that, in a head-to-head comparison of five tests used to detect SARS-CoV-2 antibodies (known as 'immunoassays'), an assay manufactured by Siemens and one developed by an academic partnership led by the University of Oxford had the most accurate results.

24 Sep 2020

Researchers uncover an active role of glycans in SARS-CoV-2 spike protein

As the COVID-19 pandemic rages on, researchers are working overtime to develop vaccines and therapies to thwart SARS-CoV-2, the virus responsible for the disease Many efforts focus on the coronavirus spike protein, which binds the angiotensin-converting enzyme 2 (ACE2) on human cells to allow viral entry.

24 Sep 2020